Quick Answer
Telomir Pharmaceuticals, Inc. reported Net Income Loss of -$10.41 million for the year ending 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +37.0% in Net Income Loss from 2024 to 2025.
- This data is from Telomir Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$482.9 thousand | Q2 2023: -$1.55 million | Q3 2023: -$1.71 million | Q4 2023: -$9.33 million | Q1 2024: -$6.25 million | Q2 2024: -$1.39 million | Q3 2024: -$5.99 million | Q1 2025: -$2.18 million | Q2 2025: -$5.07 million | Q3 2025: -$1.10 million.
- Over the full 4 years of available data (2022 to 2025), Telomir Pharmaceuticals, Inc.'s Net Income Loss has declined by 1,119.1%.
- Historical annual values: Fiscal year 2025: -$10.41 million | Fiscal year 2024: -$16.53 million | Fiscal year 2023: -$13.07 million | Fiscal year 2022: -$854.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: